新生儿持续性肺动脉高压药物治疗进展  

Drug treatment of neonatal persistent pulmonary hypertension

作　　者：王艺睿 杨宇婷 左敬叶(综述) 岳冬梅(审校)[1] Wang Yirui;Yang Yuting;Zuo Jingye;Yue Dongmei(Department of Neonatology,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院新生儿科,沈阳110004

出　　处：《中国小儿急救医学》2021年第10期914-917,共4页Chinese Pediatric Emergency Medicine

基　　金：2020年度辽宁省重点研发计划联合项目(2020JH2/10300128);辽宁省自然科学基金(201602873)。

摘　　要：新生儿持续性肺动脉高压是指新生儿出生后由于各种原因使肺动脉压力持续升高,右心压力升高,卵圆孔水平及动脉导管水平发生右向左分流,出现严重的低氧血症甚至呼吸衰竭。目前新生儿持续性肺动脉高压的药物治疗包括吸入一氧化氮、西地那非、米力农、内皮素受体拮抗剂、前列腺素及其类似物等。本文就新生儿持续性肺动脉高压治疗进展做简要综述。Neonatal persistent pulmonary hypertension refers to the continuous increase of pulmonary artery pressure,right heart pressure,right-to-left shunt at foramen ovale and ductus arteriosus level,severe hypoxemia and even respiratory failure after birth.At present,the drug treatments of neonatal persistent pulmonary hypertension include inhaling nitric oxide,sildenafil,milrinone,endothelin receptor antagonists bosentan,prostaglandins and their analogs.This review briefly summarized the progress on the treatment of neonatal persistent pulmonary hypertension.

关 键 词：新生儿持续性肺动脉高压 药物治疗 吸入型一氧化氮 西地那非 

分 类 号：R722.1[医药卫生—儿科]